Skip to content

Intrathecal Dexmedetomidine With Bupivacaine for Spinal Anesthesia in Cesarean Section

Effects of Intrathecal Dexmedetomidine on the Perioperative Clinical Profile of Bupivacaine-induced Spinal Anesthesia for Cesarean Section

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02365857
Enrollment
120
Registered
2015-02-19
Start date
2014-12-31
Completion date
2015-10-31
Last updated
2016-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Spinal

Keywords

spinal anesthesia, caesarian section, Dexmedetomidine

Brief summary

A Randomized, Controlled, Double blind study aiming to evaluate the analgesic potentials and side effect profile of different dose levels of Dexmedetomidine added to subarachnoid bupivacaine in full-term pregnant women undergoing elective cesarean section using spinal anesthesia. The investigators ultimate goal is to find out the least effective dose which will be associated with minimal or no side effects. The primary outcome will be the time to two sensory block segment regression.

Detailed description

Alpha 2-agonists are non-opioid adjuvants with a significant role in extending the analgesic duration of subarachnoid block. When clonidine or Dexmedetomidine was added to intrathecal local anesthetics, the regression of sensory and motor blocks increased dose-dependently. Further, a recent meta-analysis including seven randomized controlled studies reported an increase in the duration of analgesia and reduced morphine requirement after the concomitant subarachnoid administration of clonidine. Animal studies demonstrated that Dexmedetomidine added to bupivacaine significantly enhanced the duration of sensory and motor blockade of sciatic nerve block. Histo-pathological examination proved that all of the nerves analyzed had normal axons and myelin at 24 h and 14 days after the peri-neural administration of Dexmedetomidine. Several clinical studies confirmed the analgesic potentials and safe neurological outcome of neuraxially administered Dexmedetomidine in the non-obstetric settings while intrathecal clonidine proved to be a useful analgesic adjunct for spinal anesthesia in patients undergoing cesarean section. But to the best of the investigator knowledge the effects of intrathecal Dexmedetomidine on the perioperative clinical profile of bupivacaine-induced spinal anesthesia were not studied before in the obstetric patient population.

Interventions

Intrathecal injection of Dexmedetomidine & Bupivacaine.

DRUGBupivacaine Only.

Intrathecal injection of Bupivacaine only.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Full-term pregnant women. * Elective cesarean section using spinal anesthesia. * Singleton gestation. * American Society of Anesthesiologists (ASA) physical status classes I and II.

Exclusion criteria

* Preterm pregnancy (\<37 wks gestation). * Multiple gestation. * Cardiovascular disease (e.g., preeclampsia, hypertension) and the use of antihypertensive medication. * Conditions that preclude spinal anesthesia. * Failed spinal block and conversion to general anesthesia. * A history of established chronic pain. * Drug addiction. * A psychiatric disorder. * Inability to communicate effectively. * Asthma and allergy to non-steroidal anti-inflammatory drugs.

Design outcomes

Primary

MeasureTime frameDescription
The time to two sensory block segment regression.70 minDefine the start of regression of the level of sensory block

Secondary

MeasureTime frameDescription
Time from intrathecal injection to peak sensory block level.10 minDefine the speed of onset of the block.
Time to S1 level sensory regression.70 minDefine duration of the block.
Degree of motor block.24 hBy Modified Bromage Score.
Intraoperative hemodynamic variables.24 hDetect frequency of side effects
The total dose of ephedrine/atropine required to maintain hemodynamic stability.24 hDetect frequency of side effects
The amount of lactated Ringer's solution required intraoperatively to maintain normal Blood pressure range24 hDetect frequency of side effects
Oxygen saturation (the need for O2 supplementation)24 hDetect frequency of side effects
Intraoperative analgesic supplementation70 minDefine quality of the block
Time to first postoperative rescue analgesic request24 hDefine duration of analgesia by the block
The peak sensory level of the block.10 minBy Pin Prick testing.
Frequency of administration of postoperative analgesics24 hDefine duration of analgesia by the block
Intraoperative sedation scores24 hDetect frequency of side effects
Incidence of side effects (nausea, vomiting, shivering, pruritus, respiratory depression, and desaturation)24 hDetect frequency of side effects
New born Apgar Score5 minDetect any effects on the new born at different dose levels
Duration of motor block.24 hBy Modified Bromage Score.
Early postoperative hemodynamic variables.24 hDetect frequency of side effects
Total dose of postoperative analgesics24 hDefine duration of analgesia by the block
Postoperative sedation scores24 hDetect frequency of side effects
Postoperative pain scores for 24 hours24 hDefine duration of analgesia by the block

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026